Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,180
datasets available to search
ShareScore release 0.9.0
Dataset results
2,180 results for “clinical outcomes”
Clinical outcomes and features between the self-recognized MI group and unrecognized MI group
<p><span>Differences between the self-recognized myocardial infarction (MI) and unrecognized MI groups. A: in-hospital mortality rate. B: difference between patients previously registered with the </span><span>Korean Registry of Acute Myocardial Infarction</span><span> </span><span>(KRMI) and patients who first visited the regional cardiovascular centre (naïve). C: non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI) patients. D: rate of symptoms to balloon time within 120 mins.</span></p>
Clinical outcome prediction in COVID-19 patients by lymphocyte subsets analysis and monocytes' iTNF-α expression
<p>Raw Box & Whiskers plot related to a manuscript submitted to "Biology" journal - MDPI - https://www.mdpi.com/journal/biology - https://doi.org/10.3390/biology10080735</p> <p><strong>Manuscript Title</strong>: Clinical outcome prediction in COVID-19 patients by lymphocyte subsets analysis and monocytes’ iTNF-α expression</p> <p><strong>Authors: G</strong>abriele Madonna <sup>1†</sup>, Silvia Sale <sup>2†</sup>, Mariaelena Capone <sup>1</sup>, Chiara De Falco <sup>2</sup>, Valentina Santocchio <sup>2</sup>, Tiziana Di Matola <sup>2</sup>, Giuseppe Fiorentino <sup>3</sup>, Caterina Pirozzi <sup>2</sup>, Anna D’Antonio <sup>2</sup>, Rocco Sabatino <sup>2</sup>, Lidia Atripaldi<sup>4</sup>, Umberto Atripaldi <sup>4</sup>, Marcello Raffone <sup>5</sup>, Marcello Curvietto<sup> 1</sup>, Antonio Maria Grimaldi <sup>1</sup>, Vito Vanella <sup>1</sup>, Lucia Festino <sup>1</sup>, Luigi Scarpato <sup>1</sup>, Marco Palla <sup>1</sup>, Michela Spatarella <sup>6</sup>, Francesco Perna <sup>7</sup>, Pellegrino Cerino <sup>8</sup>, Gerardo Botti <sup>9</sup>, Roberto Parrella <sup>10</sup>, Vincenzo Montesarchio <sup>11</sup>, Paolo Antonio Ascierto <sup>1††* </sup>and Luigi Atripaldi <sup>2††</sup></p> <p><strong>Affiliations:</strong></p> <p>1 Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy</p> <p>2 UOC Biochimica Clinica, AORN Ospedali dei Colli - Monaldi – Cotugno - CTO, Napoli, Italy</p> <p>3 UOC Fisiopatologia e Riabilitazione respiratoria, AORN Ospedali dei Colli - Monaldi – Cotugno - CTO, Napoli, Italy</p> <p>4 University of Campania "Luigi Vanvitelli", Naples, Italy</p> <p>5 UOC Microbiologia e Virologia, AORN Ospedali dei Colli - Monaldi – Cotugno - CTO, Napoli, Italy</p> <p>6 UOSD di Farmacia, AORN Ospedali dei Colli - Monaldi – Cotugno - CTO, Napoli, Italy</p> <p>7 Università degli Studi di Napoli "Federico II", Naples, Italy.</p> <p>8 Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici (Na), Italy.</p> <p>9 Scientific Direction, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy</p> <p>10 UOC Malattie Infettive ad Indirizzo Respiratorio, AORN Ospedali dei Colli - Monaldi – Cotugno -CTO, Napoli, Italy</p> <p>11 UOC Oncologia, AORN Ospedali dei Colli - Monaldi – Cotugno - CTO, Napoli, Italy</p> <p>†These authors have contributed equally to this work and share first authorship</p> <p>††These authors have contributed equally to this work and share senior authorship</p> <p>*Correspondence:</p> <p><strong>Abstract of submitted Manuscript:</strong> T</p> <p>In December 2019 a novel coronavirus, “SARS-CoV-2”, was recognized as the cause of Coronavirus disease-2019 (COVID-19-disease). Several studies have explored the changes and the role of inflammatory cells and cytokines in the immunopathogenesis of disease, but until today the results have been controversial. Based on these premises, we carried out a retrospective assessment of monocytes’ intracellular TNF-α expression (iTNF-α) and on frequencies of lymphocyte sub-populations in twenty-five patients with moderate/severe COVID-19-disease. We found lymphopenia in all COVID-19 infected subjects compared with healthy subjects. On initial observation, in patients with favorable outcome we detected high absolute eosinophils count and high CD4+/CD8+ T lymphocytes ratio, while in the exitus group we observed high neutrophils and CD8+ T lymphocytes counts. During infection, in patients with favorable outcome we observed a rise in lymphocyte count, in monocytes and in Treg lymphocytes counts, in CD4+ and in CD8+ T lymphocytes count but a reduction in CD4+/CD8+ T lymphocytes ratio. Instead, in the exitus group we observed a reduction in Treg lymphocytes counts and a decrease in iTNF-α expression. Our preliminary findings point to a modulation of the different cellular mediators of immune system, which probably have a key role in the outcome of the COVID-19-disease.</p> <p><strong>Funding:</strong> This work was supported by Grants from “Regione Campania” through “POR FESR CAMPANIA 2014-2020”, CUP H64I20000300002.</p> <p><strong>Cite</strong>: Madonna, G.; Sale, S.; Capone, M.; De Falco, C.; Santocchio, V.; Di Matola, T.; Fiorentino, G.; Pirozzi, C.; D’Antonio, A.; Sabatino, R.; Atripaldi, L.; Atripaldi, U.; Raffone, M.; Curvietto, M.; Grimaldi, A.M.; Vanella, V.; Festino, L.; Scarpato, L.; Palla, M.; Spatarella, M.; Perna, F.; Cerino, P.; Botti, G.; Parrella, R.; Montesarchio, V.; Ascierto, P.A.; Atripaldi, L. Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes’ iTNF-α Expression. <em>Biology</em> <strong>2021</strong>, <em>10</em>, 735. doi: <a href="https://doi.org/10.3390/biology10080735">10.3390/biology10080735</a></p> <p> </p>
Breaking the ice to improve motor outcomes in patients with chronic stroke: a retrospective clinical study on neuromodulation plus robotics
<p>Stroke is one of the main causes of impairment affecting daily activities and quality of life. There is a growing effort to potentiate the recovery of functional gait and to enable stroke patients to walk independently. To estimate the effects of dual-site transcranial direct current stimulation (dstDCS) on gait recovery in chronic stroke patients provided with robot-aided gait training (RAGT). Thirty-seven patients were included in this retrospective clinical study. Nine patients were provided with dstDCS during the first 10 min of RAGT by using Lokomat®Pro (on-RAGT), 15 patients immediately after RAGT (post-RAGT), and 13 patients immediately before RAGT (pre-RAGT). Each group improved over time concerning disability burden and lower limb strength. on-RAGT and post-RAGT experienced better improvement in balance (p < 0.001) and, moderately, gait endurance (p = 0.04) as compared to pre-RAGT. Furthermore, all treatments decreased the facilitation of the unaffected hemisphere (p < 0.001) and the inhibition of the affected hemisphere (p < 0.001). The duration of such aftereffects was found to be greater for post-RAGT. This is the first trial with dstDCS coupled with RAGT in chronic stroke patients with gait impairment. When timely coupled with RAGT, dstDCS may be considered an effective tool for the recovery of lower limb function in patients with first unilateral stroke in the chronic phase. Moreover, our data suggest the ductility of dstDCS concerning RAGT timing, thus making this intervention suitable in a neurorehabilitation setting and well adaptable to patients’ needs. </p>
Raw Data for the article: Right vs left portal branch puncture in TIPS creation with controlled expansion covered stent: comparison of hemodynamic and clinical outcomes
<p><strong>Purpose: </strong>To retrospectively compare outcomes of TIPS performed by puncturing left portal vein (LPV) vs right portal vein (RPV) to access the portal system.</p> <p><strong>Materials and methods: </strong>One hundred ninety-three consecutive patients underwent TIPS with controlled expansion covered stent by using the LPV (37 patients) or the RPV (156 patients). Patients were followed until the last clinical evaluation, liver transplantation, or death.</p> <p><strong>Results: </strong>Demographics and clinical characteristics of the two groups were comparable. The median follow-up was 9.6 months (range 0.1-50.6). Portosystemic pressure gradient (PSG) before TIPS 15.7 mmHg ± 4.7 in RPV group (RPVG) vs 15.4 mmHg ± 4.5 in LPV group (LPVG) (p = 0.725). After TIPS, PSG 6.3 mmHg ± 2.8 in RPVG vs 6.2 mmHg ± 2.2 (p = 0.839). In LPVG, the stent was dilated to 8-mm in 95% of patients vs 77% of RPVG (p = 0.015). Two (5.4%) and 22 (14%) patients underwent TIPS revision in LPVG and RPVG (p = 0.15). The incidence of overt HE was 13% in LPVG and 24% in RPVG (p = 0.177). Rebleeding occurred in 3 of 49 patients (6%) with variceal bleeding as an indication: 2/41 patients (4.9%) in RPVG vs 1/8 patients (12.5%) in LPVG (p = 0.417). Among 126 patients with refractory ascites 20 patients (15.9%) needed paracentesis 3 months after the procedure: 18/101 patients (17.8%) in RPVG vs 2/25 patients (8%) in LPVG (p = 0.231). Thirty-seven patients (19%) died: 32 (21%) in RPVG and 5 (14%) in LPVG (p = 0.337).</p> <p><strong>Conclusion: </strong>Compared with RPV puncture, in TIPS created through the LPV, the targeted PSG was reached with a smaller stent diameter. However, no significant difference in clinical outcomes was observed.</p>
Raw Data for the article: Clinical outcomes of transjugular intrahepatic portosystemic shunt with PTFE-covered stents after liver transplantation and technical results in split and whole liver graft recipients
<p><strong>Objectives: </strong>To assess the outcomes of transjugular intrahepatic portosystemic shunt (TIPS) creation using PTFE-covered stents in liver transplant (LT) recipients and to analyze the technical result of TIPS creation in split grafts (SG) compared with whole liver grafts (WG).</p> <p><strong>Methods and materials: </strong>Single-center, retrospective study, analyzing LT patients who underwent TIPS using PTFE-covered stents. Clinical and technical variables were analyzed.</p> <p><strong>Results: </strong>Between 2005 and 2021, TIPS was created using PTFE-covered stents in 48 LT patients at a median of 43 months (range, 0.5-192) after LT. TIPS indications were refractory ascites (RA) in 33 patients (69%), variceal bleeding (VB) in 9 patients (19%), others in 6 (12%). Ten patients (21%) received a SG. Technical success rate was 100% in both groups: in two WG recipients, (5%) a second attempt was required. An unconventional approach (combined transhepatic or transplenic access) was needed in 2 WG (5%) and 2 SG recipients (20%). Two procedure-related death occurred in the WG group. After a median follow-up of 22 months (range, 0,1-144), 16 patients (48%) in the RA group did not require post-TIPS paracentesis, in the VB group rebleeding occurred in 3 patients (33%). Fifteen patients (31%) underwent TIPS revision. Overt hepatic encephalopathy occurred in 14 patients (29%). Patient survival at 6 months, 1 year, and 3 years was 77%, 66%, and 43%, respectively.</p> <p><strong>Conclusions: </strong>The feasibility and safety of TIPS creation in SG are comparable to that of WG. TIPS creation using PTFE-covered stents represents a viable option to treat portal hypertensive complications in LT recipients.</p>
Supplemental; Materials - Current state of genomics in nursing: A scoping review of healthcare provider oriented (clinical and educational) outcomes (2012-2022)
<p>Supplemental Table S1 "Scoping Review Data Extraction Table"</p>
Clinical and Refractive Outcomes After Contoura® Refractive Surgery Planned Using Phorcides Surgery Planning Software
ClinicalTrials.gov study NCT04495829. IPD Sharing: NO. Countries: 1. Publications: 3.
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
ClinicalTrials.gov study NCT00791492. IPD Sharing: Not stated. Countries: 6. Publications: 5.
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
ClinicalTrials.gov study NCT00630747. IPD Sharing: Not stated. Countries: 10. Publications: 4.
Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes
ClinicalTrials.gov study NCT01855412. IPD Sharing: Not stated. Countries: 1. Publications: 13.
Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas
ClinicalTrials.gov study NCT04917757. IPD Sharing: UNDECIDED. Countries: 2. Publications: 1.
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimum
ClinicalTrials.gov study NCT01185288. IPD Sharing: Not stated. Countries: 2. Publications: 6.
A Study of Clinical Outcomes of the REALIZE Adjustable Gastric Band-C
ClinicalTrials.gov study NCT00999661. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy
ClinicalTrials.gov study NCT04394247. IPD Sharing: NO. Countries: 1. Publications: 1.
Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19
ClinicalTrials.gov study NCT04706533. IPD Sharing: NO. Countries: 1. Publications: 19.
Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
ClinicalTrials.gov study NCT04847622. IPD Sharing: NO. Countries: 5. Publications: 1.
Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies
ClinicalTrials.gov study NCT03888222. IPD Sharing: NO. Countries: 1. Publications: 1.
The Impact of Nurse Practitioner-Led Multidisciplinary Team Intervention on the Implementation of Guideline-Directed Medical Therapy and Clinical Outcomes in Adults With Multimorbidity
ClinicalTrials.gov study NCT07138183. IPD Sharing: NO. Countries: 0. Publications: 8.
Electronic-health Application To Measure Outcomes REmotely Clinical Trial
ClinicalTrials.gov study NCT02418546. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical Outcomes Associated With the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease
ClinicalTrials.gov study NCT03733626. IPD Sharing: NO. Countries: 1. Publications: 7.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.